Microdosing, imaging biomarkers and SPECT: A multi-sided tripod to accelerate drug development

Current Pharmaceutical Design

Volumn 15, Issue 9, 2009, Pages 928-934

  Pauwels, Ernest K J ^a,b   Bergstrom, Kim ^c   Mariani, Giuliano ^a   Kairemo, Kalevi ^d  

^a UNIVERSITY OF PISA   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Imanext Ltd   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Drug development; Imaging biomarkers; Microdosing; Radionuclide imaging; SPECT

Indexed keywords

2,3 DIHYDRO 1H IMIDAZO[1,2 B]PYRAZOLE I 123; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 123; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ALTROPANE I 123; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 131; EPIDEPRIDE I 123; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INDIUM 111; IODINE 123; IODINE 125; IODINE 131; IOMAZENIL I 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE I 123; NNC 13 8241; NNC 13 8241 I 123; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TENASCIN MONOCLONAL ANTIBODY I 131; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; DRUG;

CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; DOSE CALCULATION; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; GLIOBLASTOMA; HUMAN; ISOTOPE LABELING; LUNG CANCER; LUNG NODULE; MICRODOSING; MOLECULAR IMAGING; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MEDICINE; PRIORITY JOURNAL; REVIEW; SCINTISCANNING; SERIAL ANALYSIS OF GENE EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DESIGN; METABOLISM; METHODOLOGY; PHARMACEUTICS;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; ISOTOPE LABELING; PHARMACEUTICAL PREPARATIONS; RADIOISOTOPES; TECHNOLOGY, PHARMACEUTICAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 65549136273     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582039     Document Type: Review

References (33)

1. Meikle SR, Kench P, Kassiou M, Banati RB. Small animal SPECT and its place in the matrix of molecular imaging technologies. Phys Med Biol 2005; 50(22): R45-61.
2. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol 2006; 41(3): 206-12.
3. Bergström M, Grahnén A, Längström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003; 59(5-6): 357-66.
4. Lucignani G. Imaging biomarkers: from research to patient care-a shift in view. Eur J Nucl Med Mol Imaging 2007; 34(10): 1693-7.
5. Mahmood A, Jones AG. Technetium radiopharmaceuticals. In: Welch MJ, Redvanly CS, Eds. Handbook of Radiopharmaceuticals. Radiochemistry and applications. Wiley: West Sussex 2003; pp. 323-362.
6. Alberto R, Schibli R, Egli A, Schubiger AP. A novel organometallic aqua complex of technetium for the labeling of biomolecules: Synthesis of 99mTc(OH2)3(CO)3]+ from 99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 1998; 120: 7987-8.
7. Coenen H, Mertens J, Maziere B, Eds. Radioiodination reactions for radiopharmaceuticals: Springer 2006.
8. Maecke HR, Good S. In: Vertes A, Nagy S, Klencsar Z, Eds. Radiometals and bifunctional labeling chemistry. Handbook of Nuclear Chemistry. Kluwer Academic Publishers, The Netherlands 2003; vol. 4: pp. 279-314.
9. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2(7): 566-80.
10. Schaefer-Cutillo J, Friedberg JW. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. Semin Hematol 2008; 45(2): 110-7.
11. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005; 65(2): 622-31
12. Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res 2007; 67(2): 718-26.
13. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005; 23(27): 6763-70.
14. Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007; 14(9): 2577-90.
15. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 2006; 24(1): 115-22.
16. Akabani G, Cokgor I, Coleman RE, González Trotter D, Wong TZ, Friedman HS, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 2000; 46(4): 947-58
17. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, et al. Elucidation of the mechanism enabling tumor selective pro-drug monotherapy. Cancer Res 1998; 58(6): 1195-201.
18. Wang SM. Understanding SAGE data. Trends Genet 2007; 23(1): 42-50.
19. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001; 61(18): 6649-55.
20. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9(2): 571-9.
21. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46(6): 723-34
22. Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, et al. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun 2008; 29(3): 283-90.
23. Cronin P, Dwamena BA, Kelly AM, Carlos RC. Solitary pulmonary nodules: meta-analytic comparison of cross-sectional imaging modalities for diagnosis of malignancy. Radiology 2008; 246(3): 772-82.
24. Takei T, Kuge Y, Zhao S, Sato M, Strauss HW, Blankenberg FG, et al. Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation. J Nucl Med 2005; 46(5): 794-9.
25. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3(8): 711-5.
26. Peremans K, Goethals I, De Vos F, Dobbeleir A, Ham H, Van Bree H, et al. Serotonin transporter and dopamine transporter imaging in the canine brain. Nucl Med Biol 2006; 33(7): 907-13.
27. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 2008; 83(2): 349-5
28. Document EMEA/127318/2007, European Medicines Agency, London, UK.
29. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8(7): 787-802.
30. Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends Mol Med 2007; 13(5): 183-91.
31. Bakhtiar R. Biomarkers in drug discovery and development. J Pharmacol Toxicol Methods 2008; 57(2): 85-91.
32. Bauer M, Wagner CC, Langer O. Microdosing studies in humans: the role of positron emission tomography. Drugs RD 2008; 9(2): 73-81.
33. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008; 60(12): 1329-46.